Efrat Kaduri - Pluri Chief Pharma

PLUR Stock  USD 5.27  0.37  7.55%   

Executive

Efrat Kaduri is Chief Pharma of Pluri Inc
Phone972 74 710 8600
Webhttps://www.pluri-biotech.com

Pluri Management Efficiency

The company has return on total asset (ROA) of (0.3067) % which means that it has lost $0.3067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0607) %, meaning that it created substantial loss on money invested by shareholders. Pluri's management efficiency ratios could be used to measure how well Pluri manages its routine affairs as well as how well it operates its assets and liabilities.
Pluri Inc currently holds 29.61 M in liabilities with Debt to Equity (D/E) ratio of 0.89, which is about average as compared to similar companies. Pluri Inc has a current ratio of 8.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pluri's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Eddie MBALumos Pharma
N/A
Katherine BockArcus Biosciences
N/A
Liron GalMediwound
N/A
MA JDSutro Biopharma
N/A
Yoash ZoharEvogene
57
Stephen YoungArcus Biosciences
55
Barbara HickingbottomFate Therapeutics
N/A
Andrew HenryFate Therapeutics
60
HansPeter GerberSutro Biopharma
61
Valerie MorissetEliem Therapeutics
54
Alfonso MDFoghorn Therapeutics
53
Eran DorCompugen
N/A
Henry MDCompugen
59
Linda MoreiraMAIA Biotechnology
N/A
Bahram ValamehrFate Therapeutics
47
Dorit AmitayCompugen
56
Amit resEvogene
42
David CPACompugen
40
Ety MBAMediwound
62
Anna RivkinFoghorn Therapeutics
N/A
Eran OphirCompugen
46
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. Pluri operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 154 people. Pluri Inc (PLUR) is traded on NASDAQ Exchange in USA. It is located in Building No. 5, Haifa, Israel, 3508409 and employs 106 people. Pluri is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pluri Inc Leadership Team

Elected by the shareholders, the Pluri's board of directors comprises two types of representatives: Pluri inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pluri. The board's role is to monitor Pluri's management team and ensure that shareholders' interests are well served. Pluri's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pluri's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lior Raviv, Chief Officer
Nimrod Zvi, Chief Officer
John Dvor, EVP America
Liat Zalts, Chief Treasurer
Efrat LivneHadass, Vice Resources
Yaacov Yanay, CEO President
Orly Amiran, Chief Officer
Arthur Machlenkin, Chief Officer
Chen FrancoYehuda, Treasurer CFO
Nitsan MD, Chief Officer
Efrat Kaduri, Chief Pharma

Pluri Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pluri a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Pluri

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pluri position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pluri will appreciate offsetting losses from the drop in the long position's value.

Moving against Pluri Stock

  0.61KZR Kezar Life SciencesPairCorr
  0.58MLYS Mineralys Therapeutics,PairCorr
The ability to find closely correlated positions to Pluri could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pluri when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pluri - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pluri Inc to buy it.
The correlation of Pluri is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pluri moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pluri Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pluri can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Pluri Stock Analysis

When running Pluri's price analysis, check to measure Pluri's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluri is operating at the current time. Most of Pluri's value examination focuses on studying past and present price action to predict the probability of Pluri's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluri's price. Additionally, you may evaluate how the addition of Pluri to your portfolios can decrease your overall portfolio volatility.